Prostaglandin analogues for ophthalmic use: A cost-effectiveness analysis

Canadian Journal of Ophthalmology

Volumn 43, Issue 1, 2008, Pages 33-41

  Lachaine, Jean ^a   Hodge, William G ^b   Steffensen, Isabella ^c   Murray, Christine ^c   Barnes, David ^c   Foerster, Vicki ^c   Ducruet, Thierry ^c   Mensinkai, Shaila ^d  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITY OF OTTAWA EYE INSTITUTE   (Canada)

^c Meta Business Advantage Ltd   (Canada)

^d CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

Author keywords

Cost effectiveness; Intraocular pressure; Latanoprost; Travoprost

Indexed keywords

BETAXOLOL; BIMATOPROST; BRIMONIDINE; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TRAVOPROST;

ARTICLE; CANADA; CONTROLLED STUDY; DRUG COST; ECONOMIC ASPECT; HUMAN; INCIDENCE; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; SENSITIVITY ANALYSIS;

EID: 39449093076     PISSN: 00084182     EISSN: 17153360     Source Type: Journal    
DOI: 10.3129/I07-182     Document Type: Article

References (53)

1. Statistics Canada. Population projections for Canada, the provinces and territories. Ottawa: Statistics Canada, 2006.
2. Adatia FA, Damji KF. Chronic open-angle glaucoma. Review for primary care physicians. Can Family Physician 2005;51:1229-37.
3. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20.
4. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:498-505.
5. Crichton A, Drance SM, Douglas GR, Schulzer M. Unequal intraocular pressure and its relation to asymmetric visual field defects in low-tension glaucoma. Ophthalmology 1989;96:1312-4.
6. Cartwright MJ, Anderson DR. Correlation of asymmetric damage with asymmetric intraocular pressure in normal-tension glaucoma (low-tension glaucoma). Arch Ophthalmol 1988;106:898-900.
7. Leskea MC, Heijl A, Hyman L, Bengtsson B, Komaroff E. Factors for progression and glaucoma treatment: the Early Manifest Glaucoma Trial. Curr Opin Ophthalmol 2004;15:102-6.
8. Haefliger IO, Hitchings RA. Relationship between asymmetry of visual field defects and intraocular pressure difference in an untreated normal (low) tension glaucoma population. Acta Ophthalmologica 1990;68:564-7.
9. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging 2005;22:1-21.
10. Ontario drug benefit formulary/comparative drug index [database online]. Toronto: Ministry of Health and Long Term Care; 2006.
11. Fiscella RG, Green A, Patuszynski DH, Wilensky J. Medical therapy cost considerations for glaucoma. Am J Ophthalmol 2003;136:18-25.
12. Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act: effective April 1, 2006. Toronto: Ministry of Health and Long-Term Care; 2006.
13. Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Group. Ophthalmology 1995;102:1743-52.
14. Fechtner RD, Airaksinen PJ, Getson AJ, Lines CR, Adamsons IA; COSOPT versus XALATAN Study Groups. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 2004;82:42-8.
15. Camras CB. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 1996;103:138-47.
16. Konstas AG, Mylopoulos N, Karabatsas CH, et al. Diurnal intraocular pressure reduction with latanoprost 0.005% compared to timolol maleate 0.5% as monotherapy in subjects with exfoliation glaucoma. Eye 2004;18:893-9.
17. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE. A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550-5.
18. Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M. A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension. A 12-week study. Arch Ophthalmol 1996;114:929-32.
19. Netland PA, Landry T, Sullivan EK, et al. Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84.
20. Sihota R, Saxena R, Agarwal HC, Gulati V. Crossover comparison of timolol and latanoprost in chronic primary angle-closure glaucoma. Arch Ophthalmol 2004;122:185-9.
21. Watson P, Stjernschantz J, Group TLS. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 1996;103:126-37.
22. Erkin EF, Tarhan S, Kayikcioglu OR, Deveci H, Güler C, Göktan C. Effects of betaxolol and latanoprost on ocular blood flow and visual fields in patients with primary open-angle glaucoma. Eur J Ophthalmol 2004;14:211-9.
23. Ozdemir M, Ozdemir G. Comparison of the intraocular pressure lowering effect of latanoprost and carteolol-pilocarpine combination in newly diagnosed glaucoma. Jpn J Ophthalmol 2003;47:72-6.
24. Camras CB, Sheu WP, for the United States Latanoprost-Brimonidine Study Group. Latanoprost or brimonidine as treatment for elevated intraocular pressure: multicenter trial in the United States. J Glaucoma 2005;14:161-7.
25. DuBiner HB, Mroz M, Shapiro AM, Dirks MS; Brimonidine vs. Latanoprost Study Group. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial. Clin Ther 2001;23:1969-83.
26. Inan ÜÜ, Ermis SS, Yücel A, Öztürk F. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial. Acta Ophthalmol Scand 2003;81:155-60.
27. Fellman RL, Sullivan EK, Ratliff M, et al.; Travoprost Study Group. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008.
28. Martin E, Martinez-de-la-Casa JM, Garcia-Feijoo J, Troyano J, Larrosa JM, Garcia-Sanchez J. A 6-month assessment of bimatoprost 0.03% vs timolol maleate 0.5%: hypotensive efficacy, macular thickness and flare in ocular-hypertensive and glaucoma patients. Eye 2007;21:164-8.
29. Niazi MK, Raja N. Comparison of latanoprost and dorzolamide in the treatment of patients with open angle glaucoma. J Ayub Med Coll Abbottabad 2004;16:50-3.
30. O'Donoghue EP, UK and Ireland Latanoprost Study Group. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study. Br J Ophthalmol 2000;84:579-82.
31. Kampik A, Arias-Puente A, O'Brart DP, Vuori ML; the European Latanoprost Study Group. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma 2002;11:90-6.
32. Ahmad I, Rizvi A, Sajjad AS, Ahmad UR. Comparison of latanoprost and dorzolamide in patients with open angle glaucoma. JK Science 2003;5:26-8.
33. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7.
34. Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;24:251-64.
35. Holmstrom S, Buchholz P, Walt J, et al. The cost-effectiveness of bimatoprost, latanoprost and timolol in treatment of primary open angle glaucoma in five European countries. Curr Med Res Opin 2006;22:897-905.
36. Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballéa S. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 2003;13:S30-S43.
37. Day DG, Schacknow PN, Sharpe ED, et al. A persistency and economic analysis of latanoprost, bimatoprost, of beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2004;20:383-92.
38. Le Pen C, Ligier M, Berdeaux G. Cost-effectiveness and cost-utility analysis of travoprost versus latanoprost and timolol in the treatment of advanced glaucoma in five European countries: Austria, France, Germany, The Nethetlands and the United Kingdom. J Med Econ 2005;8:67-84.
39. Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, Walker AM. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 2005;140:598-606.
40. Rouland JF, Le Pen C, Benhaddi H, Piriou E, Lilliu H, Kenigsberg P-A; the Glaucoma Study Group. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes, and costs at 2 years. Eur J Ophthalmol 2005;15:562-80.
41. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002;8:S255-61.
42. Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003;13(Suppl 4):S21-S29.
43. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003;13:S44-S52.
44. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol 2004;137:S5-S12.
45. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 2004;137:S13-6.
46. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002;8:S271-7.
47. Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002;8:S262-70.
48. Tingey D, Bernard LM, Grima DT, Miller B, Lam A. Intraocular pressure control and persistence on treatment in glaucoma and ocular hypertension. Can J Ophthalmol 2005;40:161-9.
49. Wilensky J, Fiscella RG, Carlson AM, Morris LS, Walt J. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006;141:S28-S33.
50. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 2006;141:S15-S21.
51. Stewart WC, Chorak RP, Hunt HH, Sethuraman G. Factors associated with visual loss in patients with advanced glaucomatous changes in the optic nerve head. Am J Ophthalmol 1993;116:176-81.
52. Sharma R, Khajuria R, Sharma P, et al. Glaucoma therapy: prescribing pattern and cost analysis. JK Science 2004;6:88-92.
53. Brown MM, Brown GC, Sharma S, Kistler J, Brown H. Utility values associated with blindness in an adult population. Br J Ophthalmol 2001;85:327-31.